Longevity.Technology: Can Crowdfunding Change Ovarian Aging Research (and Opinions)?
Click below to learn about our fundraising campaign to fund work relating to women's health:
Our Campaign
Invested in Her
Funding the science that closes the gap in women's health, menopause, and ovarian aging research.
Learn More →
Read the original article from Longevity.Technology here.
Author: Eleanor Garth.
The Longevity Science Foundation (LSF) has launched Invested in Her, a fundraising campaign trained on women’s health research – ovarian aging and menopause in particular, two areas that remain conspicuously underfunded despite their consequences reaching well beyond the reproductive system.
The target is $250,000 by September; more than $50,000 has already come in, and reaching the funding goal will also unlock a further $25,000 match from LongeVC. Modest, in the context of large-scale biomedical funding – but the campaign lands at a moment when the field is beginning to reckon with how far ovarian aging’s influence actually extends, touching cardiovascular, metabolic, skeletal and neurological health across the full arc of female life.
Longevity.Technology: We often hear that women’s health is underfunded; the more interesting question is what that underinvestment has cost us. Ovarian aging is not a niche reproductive concern to be politely filed somewhere between fertility and “things women are expected to get on with”; it is a systemic biological transition with consequences for cardiometabolic health, bone integrity, neurological risk, immune function and the long, uneven slope of female healthspan. That makes funding ovarian aging science not merely a matter of fairness – although it is certainly that – but a matter of scientific accuracy, economic sense and preventive medicine done properly. For decades, menopause has been filed as an endpoint, a symptom cluster or a cultural punchline, depending on the room. Geroscience asks us to see it differently: a measurable, modifiable inflection point in human biology – one with consequences that ripple outward, not downward into irrelevance. Invested in Her will not close the funding gap alone – $250,000 is not going to reverse generations of biomedical side-eye – but campaigns like this do something quieter and more durable: they shift attention, sharpen language and make it progressively harder for funders, policymakers and the longevity field itself to treat female aging biology as peripheral. Research funding is a statement of priorities. For too long, the ovary has been regarded as reproductive hardware with an inconvenient expiry date; the science increasingly suggests it is more like a conductor – and when it falters, the whole orchestra feels the change.
More than symptom management
Writing on LinkedIn to announce the campaign, LSF CEO Joshua Herring highlighted what he describes as a persistent disconnect between disease burden and research investment. Women, he noted, generally outlive men but spend more years in poor health, while the menopausal transition is associated with substantial increases in cardiometabolic, neurological and skeletal risk. That last one deserves a moment: osteoporosis prevalence is roughly five times higher in women than men, and hip fracture mortality risk is comparable to that of breast cancer. These are the kinds of statistics that reframe a conversation.
Those observations align with a growing body of research that has begun repositioning ovarian aging – not as a reproductive milestone to be noted and moved past, but as a central biological process with systemic reach. The question scientists are now pressing is whether interventions targeting ovarian aging could shift health trajectories across multiple organ systems; the answer, increasingly, looks like an emphatic yes.
The challenge, advocates argue, is that scientific interest has not always been matched by funding.
Funding the full picture
The campaign is structured around three pillars: measurement, biology and intervention. In Pillar One, researchers are developing what the LSF describes as a “menopause clock” – molecular sensors capable of tracking reproductive biomarkers in real time, shifting diagnosis from symptom-based guesswork to precision medicine. Pillar Two maps the biological mechanisms connecting ovarian aging to systemic decline: cognition, metabolism, whole-body aging. Pillar Three targets the source directly, exploring gene therapy and partial epigenetic reprogramming to slow ovarian aging and delay menopause onset. Modifiable, not inevitable – as the LSF puts it.
Building a constituency
For Herring, the campaign is as much about public engagement as it is about capital.
Speaking to Longevity.Technology, he said: “The beauty of crowdfunding is that it gives every individual to have a personal stake in what is a much greater, broader movement. Capital is absolutely required to fund research, and particularly in women’s health it has been absent for far too long.”
Rather than waiting for traditional funding structures to shift, he argues that public participation can help accelerate change.
“Instead of waiting for the larger actors we historically have depended on for advancement to invest efficiently and responsibly, we are creating a force multiplier by elevating the voice of the public and demanding that action be taken,” he told us.
That strategy reflects a wider trend across longevity and preventive medicine, where patient advocates, citizen scientists and disease communities are increasingly helping shape research priorities. Awareness matters. Attention attracts capital; capital supports research; research generates evidence.
A virtuous cycle, when it works.
The economics of neglect
Women’s health has long been affected by structural gaps in funding, clinical trial representation and public understanding. Menopause, despite being a universal experience for roughly half the population, has often occupied an awkward position between reproductive medicine, endocrinology and aging research.
These gaps run deep. Women were not federally mandated to be included in clinical trials until 1993; the FDA did not require sex-disaggregated data reporting in drug trials until 2014. Decades of drug dosages, diagnostic criteria and treatment protocols were calibrated entirely to male physiology.
That is beginning to change. Investors, policymakers and researchers are paying closer attention to female longevity; ovarian aging, once a footnote in geroscience, is sidling into the main text. The questions themselves have not changed – what drives ovarian aging, how it shapes systemic decline, whether those processes can be modified – but the appetite for answering them has sharpened.
Changing the conversation
Herring believes public momentum can ultimately influence larger funding bodies and institutions.
“In addition to the fundraising, this campaign is certainly about galvanizing and championing that public constituency, so that ovarian aging – and issues like it – are forced to be taken seriously, prioritized, invested in, and heard,” he told us.
For a field built around extending healthy years of life, that seems an increasingly difficult argument to ignore. Some conversations begin in laboratories. Others begin when enough people decide a long-standing blind spot deserves attention.
Author: Eleanor Garth.
The Longevity Science Foundation (LSF) has launched Invested in Her, a fundraising campaign trained on women’s health research – ovarian aging and menopause in particular, two areas that remain conspicuously underfunded despite their consequences reaching well beyond the reproductive system.
The target is $250,000 by September; more than $50,000 has already come in, and reaching the funding goal will also unlock a further $25,000 match from LongeVC. Modest, in the context of large-scale biomedical funding – but the campaign lands at a moment when the field is beginning to reckon with how far ovarian aging’s influence actually extends, touching cardiovascular, metabolic, skeletal and neurological health across the full arc of female life.
Longevity.Technology: We often hear that women’s health is underfunded; the more interesting question is what that underinvestment has cost us. Ovarian aging is not a niche reproductive concern to be politely filed somewhere between fertility and “things women are expected to get on with”; it is a systemic biological transition with consequences for cardiometabolic health, bone integrity, neurological risk, immune function and the long, uneven slope of female healthspan. That makes funding ovarian aging science not merely a matter of fairness – although it is certainly that – but a matter of scientific accuracy, economic sense and preventive medicine done properly. For decades, menopause has been filed as an endpoint, a symptom cluster or a cultural punchline, depending on the room. Geroscience asks us to see it differently: a measurable, modifiable inflection point in human biology – one with consequences that ripple outward, not downward into irrelevance. Invested in Her will not close the funding gap alone – $250,000 is not going to reverse generations of biomedical side-eye – but campaigns like this do something quieter and more durable: they shift attention, sharpen language and make it progressively harder for funders, policymakers and the longevity field itself to treat female aging biology as peripheral. Research funding is a statement of priorities. For too long, the ovary has been regarded as reproductive hardware with an inconvenient expiry date; the science increasingly suggests it is more like a conductor – and when it falters, the whole orchestra feels the change.
More than symptom management
Writing on LinkedIn to announce the campaign, LSF CEO Joshua Herring highlighted what he describes as a persistent disconnect between disease burden and research investment. Women, he noted, generally outlive men but spend more years in poor health, while the menopausal transition is associated with substantial increases in cardiometabolic, neurological and skeletal risk. That last one deserves a moment: osteoporosis prevalence is roughly five times higher in women than men, and hip fracture mortality risk is comparable to that of breast cancer. These are the kinds of statistics that reframe a conversation.
Those observations align with a growing body of research that has begun repositioning ovarian aging – not as a reproductive milestone to be noted and moved past, but as a central biological process with systemic reach. The question scientists are now pressing is whether interventions targeting ovarian aging could shift health trajectories across multiple organ systems; the answer, increasingly, looks like an emphatic yes.
The challenge, advocates argue, is that scientific interest has not always been matched by funding.
Funding the full picture
The campaign is structured around three pillars: measurement, biology and intervention. In Pillar One, researchers are developing what the LSF describes as a “menopause clock” – molecular sensors capable of tracking reproductive biomarkers in real time, shifting diagnosis from symptom-based guesswork to precision medicine. Pillar Two maps the biological mechanisms connecting ovarian aging to systemic decline: cognition, metabolism, whole-body aging. Pillar Three targets the source directly, exploring gene therapy and partial epigenetic reprogramming to slow ovarian aging and delay menopause onset. Modifiable, not inevitable – as the LSF puts it.
Building a constituency
For Herring, the campaign is as much about public engagement as it is about capital.
Speaking to Longevity.Technology, he said: “The beauty of crowdfunding is that it gives every individual to have a personal stake in what is a much greater, broader movement. Capital is absolutely required to fund research, and particularly in women’s health it has been absent for far too long.”
Rather than waiting for traditional funding structures to shift, he argues that public participation can help accelerate change.
“Instead of waiting for the larger actors we historically have depended on for advancement to invest efficiently and responsibly, we are creating a force multiplier by elevating the voice of the public and demanding that action be taken,” he told us.
That strategy reflects a wider trend across longevity and preventive medicine, where patient advocates, citizen scientists and disease communities are increasingly helping shape research priorities. Awareness matters. Attention attracts capital; capital supports research; research generates evidence.
A virtuous cycle, when it works.
The economics of neglect
Women’s health has long been affected by structural gaps in funding, clinical trial representation and public understanding. Menopause, despite being a universal experience for roughly half the population, has often occupied an awkward position between reproductive medicine, endocrinology and aging research.
These gaps run deep. Women were not federally mandated to be included in clinical trials until 1993; the FDA did not require sex-disaggregated data reporting in drug trials until 2014. Decades of drug dosages, diagnostic criteria and treatment protocols were calibrated entirely to male physiology.
That is beginning to change. Investors, policymakers and researchers are paying closer attention to female longevity; ovarian aging, once a footnote in geroscience, is sidling into the main text. The questions themselves have not changed – what drives ovarian aging, how it shapes systemic decline, whether those processes can be modified – but the appetite for answering them has sharpened.
Changing the conversation
Herring believes public momentum can ultimately influence larger funding bodies and institutions.
“In addition to the fundraising, this campaign is certainly about galvanizing and championing that public constituency, so that ovarian aging – and issues like it – are forced to be taken seriously, prioritized, invested in, and heard,” he told us.
For a field built around extending healthy years of life, that seems an increasingly difficult argument to ignore. Some conversations begin in laboratories. Others begin when enough people decide a long-standing blind spot deserves attention.
2026-06-17 08:19
The LSF in the News
Featured